These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Editorial comment on: systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. Greene DR Eur Urol; 2007 Sep; 52(3):744-5. PubMed ID: 17350749 [No Abstract] [Full Text] [Related]
10. Editorial comment on: systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. Trpkov K Eur Urol; 2007 Sep; 52(3):743-4. PubMed ID: 17350751 [No Abstract] [Full Text] [Related]
12. Re: Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. McDonald MW J Urol; 1998 Oct; 160(4):1442. PubMed ID: 9751386 [No Abstract] [Full Text] [Related]
13. Editorial comment on: Oncological and functional results of antegrade radical retropubic prostatectomy for the treatment of clinically localised prostate cancer. van der Poel HG Eur Urol; 2008 Mar; 53(3):561-2. PubMed ID: 17683855 [No Abstract] [Full Text] [Related]
14. Re: recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. Pruthi RS J Urol; 1998 May; 159(5):1650. PubMed ID: 9554384 [No Abstract] [Full Text] [Related]
15. [Rising Prostate Specific Antigen following treatment with curative intention]. Jakobsen H; Pedersen KV Ugeskr Laeger; 2007 May; 169(20):1907-9. PubMed ID: 17553369 [TBL] [Abstract][Full Text] [Related]
16. [Diagnostic methodology for the biochemical recurrence of prostate cancer after radical prostatectomy]. Serra AC; Narbón ES Arch Esp Urol; 2006 Dec; 59(10):1041-52. PubMed ID: 17283717 [TBL] [Abstract][Full Text] [Related]
17. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy. Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095 [TBL] [Abstract][Full Text] [Related]
19. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ J Urol; 2009 Nov; 182(5):2250-5. PubMed ID: 19758614 [TBL] [Abstract][Full Text] [Related]
20. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Partin AW J Urol; 2006 Oct; 176(4 Pt 1):1404-8. PubMed ID: 16952644 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]